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ABSTRACT
Catharanthine Modulates Mesolimbic Dopamine Transmission:
A Potential Treatment for Alcohol Use Disorder
Benjamin M. Williams
Neuroscience Center, BYU
Master of Science
Catharanthine is derived from the Catharanthus roseus plant and is an analog to ibogaine,
a drug that reduces opioid and alcohol withdrawal symptoms and decreases drug selfadministration in both animals and humans. Catharanthine has promise to be an alternative
pharmacological treatment for addiction without the adverse side effects associated with ibogaine.
The objective of this study was to evaluate catharanthine’s effects on dopamine (DA)
transmission in the mesolimbic DA system as well as determine its effects on both ethanol
withdrawal induced anxiety and drug-seeking behaviors in mice. We hypothesized that
catharanthine would inhibit evoked DA release in the nucleus accumbens (NAc) while also
reducing anxiety and drug seeking behaviors in mice. We found that superfusion of catharanthine
(1-100 µM) to mouse brain slices significantly inhibits evoked DA release in the NAc of the
striatum in a dose dependent manner, while also slowing DA reuptake through inhibition of the
dopamine transporter (DAT), measured using fast-scan cyclic voltammetry (FSCV). We
also found that intraperitoneal administration of catharanthine in live mice significantly
increases extracellular DA, measured via microdialysis with electrochemical detection.
Catharanthine inhibition of evoked DA release was significantly reduced by the non-selective
nAChR antagonist mecamylamine, the α4 nAChR antagonist dihydro-β-erythroidine
hydrobromide (DhβE) and the α6 nAChR antagonist α-conotoxin MII, suggesting that
catharanthine inhibits α4 and α6 nAChRs in the NAc. Iontophoresis and in-vivo data indicates
that catharanthine slows DA reuptake and increases extracellular DA in the NAc through partial
inhibition of DATs. Catharanthine also blocked increases in anxiety-like behavior during ethanol
withdrawal in mice in the elevated plus maze. Lastly, preliminary data suggests that catharanthine
increases both water and ethanol drinking in a 24-hour two-bottle choice drinking paradigm,
which was contrary to our hypothesis.

Keywords: addiction, catharanthine, 18-methoxycoronaridine, dopamine, alcohol, withdrawal,
anxiety, voltammetry, nucleus accumbens, nicotinic acetylcholine receptors, dopamine transporter
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INTRODUCTION
Impact of Drug Abuse
Excessive drug use negatively impacts the lives of millions of people around the world.
Addiction to drugs of abuse, especially alcohol and nicotine, places a substantial financial burden
on the U.S. economy. Alcohol use disorder (AUD) has been estimated to cost the US economy
$249 billion per year (Sacks, Gonzales, Bouchery, Tomedi, & Brewer, 2015) with an estimated
140,000 deaths annually (CDC, 2022). Cigarette smoking, of which nicotine is the main addictive
component, has been estimated to cost the US economy $169.3 billion per year (Xu, Bishop,
Kennedy, Simpson, & Pechacek, 2015) with an estimated 480,000 deaths annually (General,
2014). Alcohol Use Disorder is detrimental to the physical and mental health of those who suffer,
however AUD can be even more detrimental to family and others close to the individual (Ersche
et al., 2020). For these reasons it is critical that we find an effective treatment for AUD and other
drug use disorders.
Drugs of Abuse and the Mesolimbic Dopamine System
Dopamine is the canonical neurotransmitter implicated in movement, motivated behavior
and reward learning. Current dogma maintains that DA neuron activation and release in the
nigrostriatal DA system originating in the midbrain substantia nigra (SN) and projecting to the
dorsal striatum underlies the initiation of movement, hence its involvement in Parkinson’s disease,
wherein dopamine (DA) neurons are depleted in the SN. The mesolimbic DA system originating
in the midbrain ventral tegmental area (VTA) and projecting to the nucleus accumbens (Vuckovic
et al., 2010) of the medial temporal lobe is thought to be involved in reward from natural behaviors
such as feeding, drinking and sex (Koob & Volkow, 2010). The NAc is known as the “pleasure
center” of the brain due to the dense DAergic projections it receives from the VTA. One theory
1

states that DA release in the NAc is a scalar index of reward, however it has become evident that
DA release in the NAc is not only involved with reward, but also involved with the expectation of
reward, reward prediction error coding, learning to avoid aversive stimuli and coping with stressful
events (Berridge & Kringelbach, 2008; Cui et al., 2020; Kramar, Castillo-Diaz, Gigante, Medina,
& Barbano, 2021; Schultz, 2016). Dysregulation of this mesolimbic system is a hallmark of drugs
of abuse and has been implicated in the habit-forming actions of several addictive drugs of abuse
(Wise, 2004). Within this pathway, an increase of DA in the NAc is implicated in substance
addictions. The level of DA release by some drugs of abuse can be 10 times that produced by
naturally rewarding behaviors such as eating, drinking, and sex. However, the onslaught of DA
release is transient and often results in adaptations including progressive, compensatory lowering
of baseline DA levels during withdrawal from chronic drug abuse.
The main cell types in the NAc are γ-aminobutyric acid (GABA)-ergic medium spiny
neurons (MSNs) expressing either DA D1 or D2 receptors (D1R or D2R) and cholinergic
interneurons (CINs). D1-MSNs form a positive feedback loop in a direct pathway back to the VTA
with VTA GABA neurons increasing DA output, while D2-MSNs form a negative feedback loop
in an indirect pathway with GABA neurons in the globus pallidus (GP), which connect to
glutamate neurons in the subthalamic nuclei (STN), which excite GABA neurons in the VTA,
inhibiting DA release in the NAc (Macpherson, Morita, & Hikida, 2014). VTA GABA neurons
perform an important role in inhibiting VTA DA neurons and are an important target of
dopaminergic modulation. VTA DA neurons also form a diffuse modulatory system with multiple
brain regions, including the dorsal hippocampus, pre-frontal cortex (PFC), anterior insular cortex,
basolateral amygdala (BLA), ventral striatum (or NAc) and the anterior cingulate cortex (aCC)
(Koob & Volkow, 2010). This modulatory system is heavily involved with reward and learning.
2

Overview of Coronaridine Congeners Ibogaine, Catharanthine and 18-Methoxycoronaridine
Ibogaine is one of several terpene indole alkaloids compounds that are found in the root
bark of the African shrub Tabernanthe iboga. Ibogaine is a member of a small group of drugs
known as coronaridine congeners, including but not limited to its active metabolite noribogaine,
coronaridine, catharanthine, 18-methoxycoronaridine (18-MC), 18-hydroxycoronaridine and 18methylaminocoronaridine, which have recently gathered interest for their anti-addictive properties.
Ibogaine has been found to act on a wide variety of targets, including voltage-gated sodium
channels, kappa-opioid receptors, mu-opioid receptors, sigma receptors, NMDA glutamate
receptors, monoamine transporters, metabotropic 5-HT2 and ionotropic 5-HT3 receptors, nicotinic
acetylcholine receptors (nAChRs) and muscarinic g-protein coupled receptors (mGPCRs) (Codd,
1995; Deecher et al., 1992; Sershen, Hashim, Harsing, & Lajtha, 1992; Sershen, Hashim, & Lajtha,
1997; Sweetnam et al., 1995). Ibogaine reduces opioid and ethanol withdrawal symptoms and
decreases drug self-administration in both animals and humans (Brown & Alper, 2018;
Maisonneuve & Glick, 2003), however ibogaine has been found to increase heart arrhythmias,
induces body tremors, loss of cerebellar purkinje cells, has hallucinogenic properties and has even
lead to sudden deaths (Grogan, Gerona, Snow, & Kao, 2019; Knuijver et al., 2021; Koenig &
Hilber, 2015). For this reason, ibogaine has been classified as a schedule I substance by the DEA
in the United States and for the most part, has been prohibited as an addiction treatment. Outside
the US, ibogaine has found moderate success in treating addiction (Barber, Gardner, Savic, &
Carter, 2020; Knuijver et al., 2021), however alternative pharmacological treatments without
negative side effects are needed.
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18-methoxycoronaridine, a synthetic derivative of ibogaine, is an α3β4 nAChR antagonist
(Arias, Jin, Feuerbach, & Drenan, 2017; Arias, Targowska-Duda, Feuerbach, & Jozwiak, 2015)
and has been gathering interest over the past 20 years of research for its anti-addictive properties.
18-MC has been found to reduce self-administration of nicotine, cocaine, morphine and ethanol
(Maisonneuve & Glick, 2003; Rezvani et al., 2016; Rezvani et al., 1997) and recently has been
found to decrease neuropathic pain (Arias, Tae, et al., 2020). 18-MC was also found to decrease
extracellular dopamine in the NAc (Glick, Kuehne, Maisonneuve, Bandarage, & Molinari, 1996).
Catharanthine is also an ibogaine analog and can be derived from the African shrubs
Tabernaemontana divaricate and Catharanthus roseus. To date, no research has investigated the
effect of catharanthine on drug seeking behaviors or on DA transmission. Catharanthine is known
to inhibit nAChRs in the brain, specifically α3β4 and α9α10 nAChRs with higher potencies
compared to that for the α4β2 subtype (Arias et al., 2017; Arias, Tae, et al., 2020; Arias et al.,
2015). Catharanthine and 18-MC have been recently found to also inhibit voltage-gated N-type
calcium channels (CaV2.2), which in conjunction with α9α10 nAChR inhibition, is implicated in
the antinociceptive activity of these congeners (Arias, Tae, et al., 2020). Recent studies also
showed that catharanthine and 18-MC potentiate GABAA receptors, and this activity has been

Figure 1. Molecular structure of coronaridine congeners catharanthine, 18-methoxycoronaridine (18-MC) and ibogaine.
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associated with the observed sedative activity in mice elicited by catharanthine at high doses (63
mg/kg) (Arias, Do Rego, et al., 2020).
Role of Nicotinic Acetylcholine Receptors in Modulating Dopamine Release
Nicotinic acetylcholine receptors are pentameric ligand-gated ion channels widely
expressed on a variety of cells types throughout the brain. Nicotinic receptors are classified as
either heteromeric, expressing α, β or other subunits (e.g., α4β2 nAChRs) or homomeric receptors
expressing only one kind of subunit (e.g., α7 nAChRs). α4β2, α6 and α7 nAChRs are expressed
in the VTA (Klink, de Kerchove d'Exaerde, Zoli, & Changeux, 2001) and nAChRs containing both
α4 and α6 in particular have been shown to mediate the reward effects of ethanol (EtOH) (Liu,
Hendrickson, et al., 2013; Liu, Zhao-Shea, McIntosh, & Tapper, 2013). Striatal CINs fire
spontaneously at 2-10 Hz both in-vivo and in brain slice (Goldberg & Wilson, 2005; Reynolds,
Hyland, & Wickens, 2004; Wilson, Chang, & Kitai, 1990). CINs are important in DA modulation
through local ACh release onto DA pre-synaptic terminals in the NAc, which are known to express
α6β2β3, α6α4β2β3 and α3β2 nAChRs (Exley & Cragg, 2008). Activation of nAChRs allow
calcium to flow through the membrane, depolarizing the pre-synaptic terminal, which removes
Mg2+ ions blocking the NMDA ion channel, causing more calcium to flow into the terminal (DajasBailador & Wonnacott, 2004; Dani, 2001). The extra calcium binds to synaptic proteins initiating
vesicle fusion and subsequent neurotransmitter release (Hu et al., 2002; Miklavc & Frick, 2011).
However, nAChRs quickly desensitize, leading to short bursts of striatal DA release (Cuevas &
Berg, 1998; Grady, Wageman, Patzlaff, & Marks, 2012; Pidoplichko et al., 2004). Optogenetic
activation of striatal CINs causes DA release in the NAc through activation of nAChRs expressed
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on dopamine pre-synaptic terminals, which supports the role of nAChRs and CINs in dopamine
release (Brimblecombe et al., 2018).
Interactions Between Ethanol and Nicotine: Role of nAChRs
It is known that ethanol elevates dopamine release in-vivo in the NAc via inhibition of
VTA GABA neurons (Lof, Ericson, Stomberg, & Soderpalm, 2007; Ludlow et al., 2009).
However, high doses of ethanol have been shown to inhibit DA release when applied to brain slices
by activating GABAA and glycine receptors (Yorgason, Ferris, Steffensen, & Jones, 2014;
Yorgason, Rose, McIntosh, Ferris, & Jones, 2015). Interestingly, EtOH has also been shown to
potentiate nAChRs, particularly α3β4 nAChRs (Abburi & McDaid, 2021). Mecamylamine, a
nonspecific nAChR antagonist, reduces self-administration of ethanol in mice, suggesting that
nAChRs as an important target for ethanol pharmacology (Bhutada et al., 2012; Ericson,
Blomqvist, Engel, & Soderpalm, 1998; Ford et al., 2009).
Multiple brain regions also regulate VTA DA release to the NAc, such as the habenula and
the laterodorsal tegmental nucleus (LDTg). Activation of glutamatergic neurons in the LDTg
results in increased DA release in the NAc via activation of nAChRs and glutamate receptors on
VTA DA neurons (Forster & Blaha, 2000). The habenula is a small brain structure located
posterior to the thalamus and adjacent to the third ventricle, subdivided into the medial habenula
(MHb), which modulates ACh transmission, and lateral habenula (LHb), which modulates
norepinephrine and serotonin transmission. The habenula is critical in modulating reward through
exciting GABAergic neurons in the rostromedial tegmental nucleus (RMTg), which inhibit VTA
GABA neurons, thereby disinhibiting VTA DA neurons (Velasquez, Molfese, & Salas, 2014).
Local administration of 18-MC into the MHb has been shown to decrease morphine selfadministration in mice, through acting on α3β4 nAChRs. However, local administration of 18-MC
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into the VTA did not affect self-administration of morphine (Glick, Ramirez, Livi, &
Maisonneuve, 2006). This is likely due to the lack of α3β4 nAChRs expressed in the VTA. It is
unknown what the effect would be of local administration of 18-MC or catharanthine into the
nucleus accumbens.
Rationale and Hypothesis
It is well established that coronaridine congeners such as ibogaine and 18methoxycoronaridine induce anti-addictive effects, particularly in reducing nicotine and ethanol
self-administration in animals. No research to date has investigated catharanthine, an ibogaine
analog, in reducing drug self-administration or on dopamine dynamics. We hypothesized that
catharanthine will induce anti-addictive effects through two mechanisms: elevating extracellular
dopamine, thereby alleviating drug craving, and inhibiting dopamine release in the NAc, which
would reduce the rewarding effects of drugs. Additionally, we hypothesized that administration of
catharanthine in-vivo will inhibit EtOH self-administration in a 24-hour 2 bottle choice paradigm
and alleviate anxiety during EtOH withdrawal in EtOH dependent mice.
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METHODS
Brain tissue preparation
C57BL/6J mice were anesthetized with isoflurane (Patterson Veterinary, Devens, MA) and
were sacrificed by decapitation. Brains were rapidly removed and transferred into ice-cold, preoxygenated (95% O2/5% CO2) artificial cerebral spinal fluid (ACSF) consisting of (in mM): NaCl
(126), KCl (2.5), NaH2PO4 (1.2), CaCl2 (2.4), MgCl2 (1.2), NaHCO3 (25), glucose (11), pH
adjusted to 7.4. Tissues were sectioned into 220 μm-thick coronal slices containing the striatum
with a vibratome tissue slicer (Leica VT1000S, Vashaw Scientific, Norcross, GA). Brain slices are
placed in a submersion recording chamber (Warner Instruments, Hamden, CT, USA) that was
modified to prevent leakage (i.e., static flow system) and bubbled with 95% O2/5% CO2 gas to
maintain pH at 7.2–7.4 and perfused at 1 ml/min at 36 °C with oxygenated ACSF.
Carbon Fiber Electrodes and Fast Scan Cyclic Voltammetry
For fast scan cyclic voltammetry (FSCV) recordings, carbon fiber electrodes were prepared
by inserting a 7.0 μm diameter carbon fiber into borosilicate glass capillary tubing (1.2 mm outer
diameter; A-M Systems, Sequim, WA, USA) under negative pressure and subsequently pulled on
a vertical pipette puller (Narishige, East Meadow, NY, USA). The carbon fiber electrode (CFE)
was then cut under microscopic control with 30-70 μm of bare fiber protruding from the end of the
glass micropipette. The CFE was backfilled with 3 M KCl. Voltammetric recordings of dopamine
signals were performed and analyzed using Demon Voltammetry and Analysis Software (Demon
Voltammetry and Analysis; Yorgason, Espana, & Jones, 2011). The carbon fiber electrode (7 μm
X ~150 μm) potential was linearly scanned as a triangular waveform from -0.4 to 1.2 V and back
to -0.4 V at a scan rate of 400 V/s. Cyclic voltammograms were recorded at the carbon fiber
electrode every 100 msec by means of a potentiostat (Dagan Corporation, Minneapolis, MN).
8

Dopamine release was evoked every 2 min
through a bipolar stimulating electrode. Fig. 2
demonstrates that dopamine becomes oxidizes
into dopamine-o-quinone at 0.6 V on the initial
voltage ramp and then reduces back to dopamine
at -0.2 V upon the downward voltage ramp.
Single pulse baseline dopamine signals were
collected (0.5 msec, 350 μA) until signals were
stable across 4-5 collections. Catharanthine was
then dissolved into ACSF and applied on the slice
via bath application.
In frequency response experiments, each
drug application including the control was first
stabilized with single pulse recordings to stabilize
the drug effect. Following the stabilization

Figure 2. Analysis of dopamine via Fast Scan
Cyclic Voltammetry (FSCV). (A) Dopaminergic presynaptic terminals release dopamine (DA), which is
subsequently converted to DA-o-quinone and reduced
back to DA upon exposure to a triangular waveform
that is applied through a carbon fiber electrode. The
magnitude of the oxidation/reduction is measured by
a respective change in current. (B) The y-axis is a point
system ranging from 0 to 1000 representing the voltage
ramp (-0.4V to 1.2V to -0.4V) is plotted against time
on the x-axis with color coded changes in current on
the z-axis shown here with the DA oxidation peak at 5
seconds, 300 points (0.6V).

period, a protocol was run to test the effect of
multiple pulses stimulating at different frequencies. The program was written in the Demon
voltammetry program to have 3 single pulse baseline recordings, followed by five more recordings,
each at 5 rapid pulses at the frequencies 10, 20, 40, 80 and 200 Hz.
Iontophoresis
Iontophoresis is a similar technique to FSCV in that it used CFEs inserted into a mouse
brain slice to measure DA kinetics, except DA is exogenously applied through a second electrode
9

instead of electrically evoking a physiological dopamine response from the brain slice.
Iontophoresis specifically measures the reuptake of exogenously applied DA into the slice through
DA transporters (DATs). Application of DA saturates the DATs, allowing us to fit the curve to the
Michaelis-Menten equations to calculate Km and Vmax.
Patch clamp electrophysiology
Horizontal brain slices (250–300 mm thick) were obtained from transgenic ChAT mice
viral injected with channel rhodopsin 2 (ChR2) inserted into the membrane of striatal cholinergic
interneurons (CINs) using a vibratome slicer. Slices were maintained at 36 degrees Celsius in
oxygenated ACSF and visualized with infrared interference contrast microscopy. A glass pipette
was pulled with a micropipette puller to have a sharp tip and is filled with 150 mM NaCl. The
pipette is placed close to a neuron in the slice while applying positive air pressure through the
pipette until it is resting directly on the membrane of the neuron. Then the positive air pressure is
released, and a seal is formed between the pipette and the neuron. In our experiments, we aimed
to obtain a “loose patch” between 10-50 MΩ between the membrane and the pipette to enable us
to record the firing rate of the cell. We compared the difference in firing rate in CINs between pre
and post drug administration.
Oocyte Electrophysiology
Protocols (No. 17-07020) for obtaining oocytes from Xenopus laevis frogs were approved
by the University of Utah’s Institutional Animal Care and Use Committee. Frogs were purchased
from Xenopus1 (Dexter, MI, USA) and maintained by university personnel in an AAALAC
accredited facility. Oocytes were obtained from frogs anesthetized with 0.4 % wt/vol Tricaine-S
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(Thermo Fisher Scientific, Waltham, MA, USA) and were sacrificed after removal of the ovarian
lobes.
Methods for the preparation of cRNA constructs for expression of nAChRs in Xenopus
laevis oocytes have been previously described (Hone et al., 2018). Clones for human β2, β3, β4
and the rat α6/α3 construct were provided by J. Garrett (Cognetix, Salt Lake City, UT, USA). The
human α6/α3 construct was provided by J.M. Lindstrom (University of Pennsylvania,
Philadelphia, PA, USA), and rat β2, β3, and β4 clones were provided by C. Luetje (University of
Miami, Miami, FL, USA). The α6/α3 constructs were used because injection of oocytes with
cRNAs encoding human or rat α6 subunits results in few or no functional receptors when coexpressed with β2 and β3 subunits (Dowell et al., 2003; Kuryatov, Olale, Cooper, Choi, &
Lindstrom, 2000). Furthermore, functional human α6β4 nAChRs also fail to express in oocytes
(Hone et al., 2021). For the purposes of this work, α6/α3 refers to the chimeric expression construct
used here for functional studies of α6/α3β2β3 and α6/α3β4 nAChRs in oocytes.
Stage IV-V oocytes were injected with equal ratios cRNAs encoding cloned human or rat
nAChR subunits and subjected to two-electrode voltage-clamp electrophysiology 3-5 days after
injection. The concentrations of acetylcholine (ACh) used were 100 μM for α6/α3β2β3 and 300
μM α6/α3β4 nAChRs. ACh was applied at 60 s intervals for one second. For the assessment of
(+)-catharanthine activity, oocytes were continuously perfused with frog saline (control solution)
consisting of 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1.0 MgCl2 and buffered to pH 7.4 with 5
mM HEPES and NaOH. Bovine serum albumin 0.1% (wt/vol) was added to all solutions to prevent
non-specific adsorption of the compound to the tubing and glassware. The oocyte membranes were
clamped at a holding potential of -70 mV and stimulated with ACh for 1 s once every 60 s, until a
11

stable baseline-response was observed. The saline was then switched to one containing the
antagonist and the ACh responses monitored for changes in amplitude. (+)-Catharanthine sulfate
was prepared as 10 mM stock solutions in distilled water and added to perfusion solution to obtain
concentrations in the 0.1-100 µM range. Each concentration was perfused until a steady-state level
of inhibition of the ACh-gated currents was observed.
Microdialysis
Using a surgical drill, a small hole was created in the skull of a mouse at the coordinates
1.5mm anterior of bregma, 0.9 mm lateral of midline to give access to the NAc. A microdialysis
probe (MD-2211 1mm Membrane Probe, BASi Instruments) was lowered 4.2 mm into the NAc.
The probe was used to flow artificial cerebrospinal fluid (aCSF) at a rate of 1-2 uL/min. The
dialysate samples were collected every 20 min for two hours after injection. The samples were
analyzed using a Thermo Fischer Ultimate 3000 High Performance Liquid Chromatography
(HPLC) instrument with detection by a Coulochem III electrochemical detector. This technique
determined how much DA is in each sample in order to monitor its levels over time.
Elevated Plus Maze
The elevated plus maze (EPM) paradigm is used to measure anxiety related behaviors. The
EPM apparatus consists of a "+" shaped maze elevated above the floor with two oppositely
positioned enclosed arms with high walls, two oppositely positioned open arms with no walls and
a center area between the four arms. Each mouse is placed into the center of the maze and then
allowed to roam freely for 5 min while being timed. The time that a mouse spends in the open
arms of the maze corresponds with a lack of anxiety. An increase in time spent in the open arm
from pre-treatment to post-treatment indicates an anxiolytic effect elicited by the drug under study.
12

Marble burying
Mice in the natural environment often bury their food or other objects when stressed. The
marble burying test takes advantage of this instinctive behavior to measure anxiety-like behavior
in mice. Each mouse is placed in a container filled half-way with corncob bedding with a set
number of marbles placed in a grid inside. After 30 min, the number of marbles that were more
than three-quarters buried were counted. We compared the number of marbles buried between
mice that received saline (control) and catharanthine injections.
24-hour two-bottle choice drinking
Mice were given continuous access to 2 water bottles placed on either side of a cage. After
a 1-week habituation period, mice were given 15% EtOH in one bottle and water in the other.
Bottle weights were measured multiple times a day to quantify amount drank in grams. Each day,
the bottle placement was switched to reduce the possibility of conditioned-place preference. Mice
were subsequently exposed to EtOH vapors in a chronic intermittent exposure (Martinez-Pinilla et
al., 2020) model of 4 days on, 3 days off. Drinking was measured again following 4-5 weeks of
exposure to EtOH vapor.
Statistical analysis
Dopamine release was analyzed in Demon Voltammetry software (Yorgason et al., 2011)
and measured at peak oxidation currents. The software performs a running subtraction of
capacitative currents to account for changes in extracellular DA levels and to reduce noise. Postsubtracted data is then compared across time against calibrated DA cyclic voltammograms, from
which it calculates an r2 value to measure signal clarity. Statistics were performed in R studio and
figure creation was done in IGOR Pro (Wavemetrics, Lake Oswego, OR). Single ANOVAs were
used to compare concentration specific differences between drug applications with Tukey HSD
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correction method for post-hoc analysis. Linear regression models were fit on catharanthine/ 18MC dose response curves to measure correlation between DA release and concentration of
coronaridine congeners.
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RESULTS
Effect of Coronaridine Congeners on Dopamine Release and Dopamine Kinetics
Fast scan cyclic voltammetry (FSCV), which is the technique used here to determine the
effects of catharanthine on dopamine (DA) release and kinetics, is an electrochemical technique
capable of quantitatively measuring DA release through depolarizing nearby DA terminals via a
simulating electrode. Further analysis of the time and velocity of the downward side of the DA
curve can reveal the level of DA reuptake through dopamine transporters (DATs). It is known that
catharanthine inhibits nicotinic acetylcholine receptors (nAChRs), so we hypothesized that
catharanthine would inhibit evoked DA release. Catharanthine is already known to inhibit both the
serotonin transporter (SERT) and the DAT, which would elevate baseline DA levels, however due
to FSCV employing background subtraction, any effect catharanthine has on basal levels of DA
should be subtracted out in the DA peak. We also know that 18-MC has the opposite effect of
reducing basal DA levels making it unlikely that 18-MC similarly inhibits the DAT. Additionally,
catharanthine is known to inhibit α3 and α9α10 nAChRs subunits, therefore, since α3 nAChRs
subunits are expressed on DA terminals in the NAc, catharanthine should inhibit DA release,
which is what we observed (Fig. 3A, B). A color plot representation of scanning for dopamine
release over a range of voltages (y-axis) over time (x-axis) with corresponding increases in current
(z-axis) with subsequent inhibition by catharanthine is shown (Fig. 3B).
We found that both catharanthine base and catharanthine sulfate significantly inhibit DA
release in the NAc in a concentration dependent manner with half maximal inhibitory
concentrations (IC50s) of 30 and 20 µM respectively (Fig. 3C). Catharanthine base significantly
inhibits DA release at 30 and 100 µM in an ANOVA model with Tukey adjustment (overall: F =
15

35.91, p = 1.914e-10, 30 µM: 95% confidence intervals (CI) [-67.2, -26.9], p < 0.0001; 100 µM:
95% CI [-107.0, -57.5], p << 0.0001, Fig. 3C). Catharanthine sulfate, which has additional sulfate
groups added to improve solubility, significantly inhibits DA at 10, 20 and 30 µM (overall: F =
32.54, p = 6.099e-10, 10 µM: 95% CI [-53.4, -2.3], p = 0.0267, 20 µM: 95% CI [-74.7, -23.6], p
= 0.0000506; 30 µM: 95% CI [-108.3, -59.6], p << 0.0001, Fig. 3C). There are no results with
catharanthine sulfate at 100 µM due near complete inhibition of the DA signal at 30 µM. 18-MC
also significantly inhibits evoked DA release in the NAc, but only to 79.6% of the baseline at 100
µM (F = 3.830, p = 0.00658, Fig. 3C). Fitting a linear regression to our model with an adjusted rsquared of 0.4204, we see that catharanthine base and catharanthine sulfate inhibit DA release
significantly more than 18-MC across all doses (t = -2.578 and -4.630, p = 0.0114 and 1.08e-05
respectively, Fig. 3C). In this model, we also see that concentration significantly predicts DA
release across the 3 different drugs (t = -8.298, p = 4.59e-13, Fig. 3C). Adjusting our regression
model to compare against catharanthine base, we see that catharanthine sulfate inhibits DA release
significantly more than catharanthine base across all doses (t-value = -2.019, p = 0.0461, Fig. 3C).
Comparing the three coronaridine congeners at 30 µM, we see that catharanthine base and
catharanthine sulfate significantly inhibit DA release more than 18-MC (F = 5.94 and 13.01, p =
0.0288 and 0.0036 respectively, Fig. 3D). Catharanthine base inhibits DA release more than 18MC at 100 µM (F = 15.19, p = 0.00297, Fig. 3E).
Analyzing the DA curve, we can determine the effects of catharanthine on DA reuptake
using FSCV. Catharanthine base significantly slowed the downward side of the DA curve at 30
and 100 µM, increasing the time it takes for DA to return into the DA pre-synaptic terminals in an
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Figure 3. The effects of coronaridine congeners 18-methoxycoronaridine (18-MC), catharanthine base
and catharanthine sulfate on evoked DA release and reuptake. (A) Example current trace (I/T)
demonstrating DA release with overlaid effect of catharanthine base (30 μM). (B) Corresponding 3dimensional color plots (V/T over I) demonstrating DA signal and effect of catharanthine base (30 μM).
(C, D, E) Comparison of 18-MC, catharanthine base (cath base) and catharanthine sulfate (cath sulfate)
on DA peak height. (D) In depth comparison at 30 μM. (E) In depth comparison at 100 μM. (F, G, H)
Comparison of 18-MC, cath base and cath sulfate on DA reuptake, measured by Tau. (G, H) similar to
(D, E). (I, J, K) Comparison of 18-MC, cath base and cath sulfate on downward velocity (DvDtDown),
a second measure of reuptake. 100uM DvDtDown data not included due to inaccuracies of this variable
becoming more pronounced with smaller signals. (J, K) similar to (D, E). Asterisks *, ** and ***
indicate p < 0.05, p < 0.01 and p < 0.001 respectively.
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ANOVA (overall: F = 6.7266, p = 0.000683; 30 µM: t = 3.401, p = 0.002105; 100 µM: t = 4.3, p
= 0.000199, Fig. 3F). Catharanthine sulfate also significantly slows DA reuptake, increasing tau
at 30 µM (t = 2.726, p = 0.0123, Fig. 3F). 18-MC only significantly slows DA reuptake at 100 µM
(t = 2.061, p = 0.0462, Fig. 3F). There were no significant differences in tau between catharanthine
base, catharanthine sulfate or 18-MC at 30 µM (Fig. 3G). Catharanthine base significantly
increased tau compared to 18-MC at 100 µM, indicating that catharanthine has a higher affinity
for the DAT than 18-MC (F = 8.79, p = 0.0142, Fig. 3H). Fitting a linear regression model to our
data with adjusted r2 = 0.1959, catharanthine base and catharanthine sulfate inhibit DA reuptake,
significantly increasing tau more than 18-MC (F = 2.674 and 3.086, p = 0.00875 and 0.00262
respectively, Fig. 3F). Adjusting our regression model to compare against catharanthine base, we
see that catharanthine sulfate does not significantly inhibit DA reuptake more than catharanthine
base (F = 0.537, p = 0.592, Fig. 3F).
Catharanthine base significantly slowed the downward velocity (DvDtDown) of the DA
curve at 30 µM, but not at 100 µM, due to the sensitivity of this variable to fluctuations in the
current traces, which are present at increased inhibition of DA at higher doses of catharanthine
(Fig. 3I). We observed a significant difference in DvDtDown between catharanthine base and 18MC, further supporting the idea that catharanthine base has greater affinity for the DAT than 18MC (F = 11.44, p = 0.00447, Fig. 3J). Additionally, catharanthine base slows DvDtDown more
than catharanthine sulfate significantly more at 30 µM (F = 7.107, p = 0.022, Fig. 3J). Oddly,
catharanthine sulfate did not slow DvDtDown significantly across the concentrations. There was
no significant difference between catharanthine base and 18-MC at 100 µM (Fig. 3K). Fitting a
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linear regression model to our data, we did not observe any significant difference between
catharanthine base, catharanthine sulfate or 18-MC across concentrations (Fig. 3I).
Pharmacology of catharanthine
In isolating the mechanism of action for catharanthine induced inhibition of DA release,
we tested a variety of receptor antagonists in the presence of catharanthine in slice. We first tested
nAChR antagonists α-conotoxin MII, dihydro-β-erythroidine (DHβE) and mecamylamine, which
are α6, α4 and a general nAChR antagonists, respectively. We observed that DHβE 300 nM and
1 µM significantly inhibited DA release on their own to 38.9% and 46.2% of the baseline with
standard error 7.73 and 11.17 respectively (F = 59.5 and 13.08, p = 0.000249 and 0.00681
respectively). Mecamylamine 2 µM and 10 µM also significantly inhibited DA release to 44.9%
and 35.5% of the baseline with standard error 7.97 and 9.06 respectively (F = 47.59 and 51.83, p
= 1.65e-05 and 0.000364). MII (500 nM) did not significantly inhibit DA release on its own.
Catharanthine sulfate (20 µM) induced inhibition of dopamine (DA) release is completely
blocked by α6 and α4 nAChR antagonists MII and DHβE respectively and partially blocked by
general nAChR antagonist mecamylamine in a concentration dependent manner (Fig. 4A, B).
Example current traces demonstrate no change in peak height following bath administration of
catharanthine sulfate (20 µM) (Fig. 4A). Catharanthine still inhibits DA release in the presence of
300 nM DHβE (F = 21.51, p = 0.00355), but not in the presence of 1 µM DHβE (F = 2.273, p =
0.17, Fig. 4B). Catharanthine also still inhibits DA release in the presence of 2 µM mecamylamine
(F = 38.64, p = 4.48e-05), but it does not with 10 µM mecamylamine (F = 2.917, p = 0.139, Fig.
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Figure 4. Mechanism of action for catharanthine sulfate in inhibition of DA release in the NAc. (A)
Example current traces of nicotinic acetylcholine receptor (nAChR) antagonists α-conotoxin MII, DHβE
and mecamylamine (Meca) with and without catharanthine sulfate (20 µM), normalized to the addition of
the nAChR antagonist. (B) Effect of various nAChR antagonists on blocking catharanthine induced
inhibition of DA release in the NAc. (C) Example current traces of receptor antagonists for voltage-gated
calcium channels (cadmium), GABAA receptors (picrotoxin), DA D2 receptors (eticlopride) and delta
opioid receptors (naltrexone). with catharanthine sulfate (20 µM). (D) Effect of other receptor antagonists
on blocking catharanthine induced inhibition of DA release in the NAc. Asterisks * and ** indicate p <
0.05 and p < 0.01 respectively, ns = no significance. # indicates statistical significance to catharanthine
sulfate control group.

4C). Our results also indicate that catharanthine is blocked in the presence of 500 nM a-conotoxin
MII with catharanthine normalized to administration of MII, inhibiting DA release to 93% of the
baseline with standard error of 2.73, however this effect is significant in a one-way ANOVA (F =
7.045, p = 0.0189, Fig. 4C). Catharanthine sulfate (20 µM) inhibits DA release significantly more
than catharanthine sulfate in the presence of DHβE 1 µM, mecamylamine 10 µM and MII (500
nM) in a two-way ANOVA with Tukey adjustment (95% CIs [21.7, 65.8], [6.92, 53.6] and [21.5,
61.2], p = 0.0001342, 0.0087405 and 0.0000755, Fig. 4B).
To determine whether catharanthine acts on other receptors previously reported as targets
for ibogaine, we tested catharanthine in the presence of cadmium, picrotoxin, eticlopride and
naltrexone, which are antagonists for voltage-gated calcium channels, GABAA receptors, DA D2
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receptors (D2Rs) and delta opioid receptors (DORs) respectively. Cadmium significantly inhibited
DA release on its own to 50.8 ± 7.58 % of the baseline (F1,6 = 38.58, p = 0.000804), however the
other antagonists picrotoxin, eticlopride and naltrexone did not significantly affect DA release on
their own (F1,6 = 0.747, p = 0.421; F1,4 = 1.032, p = 0.367; F1,4 = 0.173, p = 0.695 respectively).
Catharanthine sulfate (20 µM) did significantly inhibit DA release in the presence of cadmium,
picrotoxin, eticlopride and naltrexone (F1,6 = 44.64, p = 0.000545; F1,6 = 3266, p = 1.93e-09; F1,4
= 14, p = 0.0201; F1,4 = 1228, p = 3.96e-06; respectively, Fig. 4D).
Catharanthine slows dopamine reuptake in a concentration dependent manner
Following vesicular release of DA in the brain, DA is funneled back into the pre-synaptic
terminals through DATs. Using FSCV, evoked DA signals can transiently increase or decrease
over time, changing the amount of DA reuptake observed, thus making it less efficient in
measuring DA reuptake. Iontophoresis can more directly measure DA reuptake by externally
applying a fixed amount of DA to the slice and recording the change in current as DA is funneled
into the pre-synaptic terminals.
Using

iontophoresis,

we

can

evaluate DA reuptake and thereby
Figure 5. Catharanthine inhibits DA reuptake through inhibition of the
DAT. (A) Example current trace demonstrating effect of iontophoretically
applying DA to a brain slice before and after exposure with catharanthine
base (30 μM). DA reuptake through DA transporters (DAT) is measured
through the downward side of the current trace. Catharanthine base (30
μM) slows DA reuptake through blocking the DAT. (B) DA reuptake is
slowed in a concentration dependent manner via catharanthine. Asterisks *,
** and *** indicate p < 0.05, p < 0.01 and p < 0.001 respectively.

measure the activity of the DAT.
We

hypothesize

catharanthine’s

that

due

affinity

to
for

inhibiting the DAT, catharanthine

will slow reuptake of iontophoretically applied DA in a concentration dependent manner.
Following external application of DA, we observe a sharp increase in current with subsequent
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slowing of the downward slope of the curve with 30 µM catharanthine sulfate (Fig. 5A). We found
that catharanthine significantly slowed DA reuptake, increasing tau across all doses in a linear
regression model (F1, 31 = 27.84, p = 9.71e-06, Fig. 5B). In a two-way ANOVA with Tukey
adjustment, catharanthine sulfate increases tau at 30 and 100 µM (95% CIs [0.066, 0.44] and [0.13,
0.51], p = 0.00379 and 0.000212, Fig. 5B).
Catharanthine inhibits cholinergic interneuron excitability in the nucleus accumbens core
Next, we investigated whether catharanthine would have any effect on the firing rate of
striatal cholinergic interneurons (CINs). It is known that CINs modulate DA levels through local
acetylcholine release onto pre-synaptic DA terminals expressing nAChRs. Thus, we hypothesized
that catharanthine would inhibit DA release through inhibition of striatal CINs. To confirm this
hypothesis, we patched onto CINs in the NAc in a cell-attached voltage-clamp configuration with
a “loose seal” from 10-50 MΩ to enable recording of firing rate of the neuron. Bath application of
catharanthine sulfate in increasing concentrations demonstrated inhibition of CIN firing rate (Fig.
6A). Fitting a linear model to our curve with an adjusted r2 = 0.6914, catharanthine sulfate
significantly inhibited CIN firing rate (F1, 25 = 59.26, p = 4.705E-08, Fig. 6B). In a two-way
ANOVA, we found that catharanthine sulfate specifically inhibits CIN firing rate at 10, 20, 30 and
100 µM (t = -2.70, -2.38, -4.85 and -7.74, p = 0.0137, 0.0273, 9.62e-05 and 1.91e-07 respectively,
Fig. 6B).
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To determine the specificity of
catharanthine

in

inhibiting

nAChR with α6 and α3 subunits,
we used cell cultures of oocytes
specially

derived

to

express

α6/α3β4 and α6/α3β2β3 nAChRs.
We then used 2 electrode voltageclamp with a holding potential of
Figure 6. Catharanthine inhibits striatal cholinergic interneurons (A,B) Firing
rate recordings were obtained via patch clamp electrophysiology on
cholinergic interneurons (CINs) in the nucleus accumbens. (A) Example
recordings with catharanthine sulfate (30 μM) (B) Dose response curve for
catharanthine sulfate. (C,D,E) . Effect of (+)-catharanthine on human and rat
α6/α3β4 and α6/α3β2β3 nAChRs expressed in Xenopus oocytes. (C,D) AChevoked responses of α6/α3β2β3 or α6/α3β4 receptors were recorded at 100
μM and 300 μM ACh, respectively, using two-electrode voltage-clamp at a
holding potential of -70 mV. (C,D) Examples of current traces from oocytes
expressing human α6/α3β4 (C) or rat α6/α3β2β3 (D) nAChRs, and the
inhibition produced by 100 µM (+)-catharanthine (red traces). (c)
Concentration-response curves for (+)-catharanthine (mean ± SD; n = 4
independemt determinations) at rat (●) and human (○) α6/α3β4 nAChRs and
rat (Δ) and human (▲) α6/α3β2β3 nAChRs, gave IC50 values of 3.7 ± 0.5
μM and 10.6 ± 1.4 (rat) and 3.1 ± 0.6 μM and 9.8 ± 1.7 μM (human),
respectively. Asterisks *, ** and *** indicate p < 0.05, p < 0.01 and p <
0.001 respectively.

-70mV and bath applied 100 µM
acetylcholine (ACh) to stimulate
the nAChRs. We subsequently
bath

applied

catharanthine,

100
which

µM
completely

blocked the ACh induced currents
(Fig. 6E).

Effect of catharanthine on in-vivo dopamine dynamics
Although catharanthine had fairly robust effects on evoked DA release in the slice
preparation ex-vivo, we wanted to determine if it was active in-vivo. We know that catharanthine
has specificity for the DAT, thus we hypothesized that catharanthine would increase extracellular
DA levels. In contrast, 18-MC is known to decrease extracellular DA levels, however the
mechanism

is

unknown.

We

injected

catharanthine

intraperitoneally

(IP)

into

an

anesthetized mouse and collected DA samples via microdialysis every 20 min. Catharanthine base
significantly
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elevated extracellular DA levels in a dose
dependent manner in a linear regression
model (F1,33 = 8.09, p = 0.00758, Fig. 7B).
In a two-way ANOVA with Tukey HSD
adjustment,

catharanthine

base

significantly elevates extracellular DA at 5,
10, 20 and 50 mg/kg (95% CIs [43.7,
336.6], [100.9, 393.7], [100.2, 393.2] and

Figure 7. Catharanthine elevates extracellular DA levels in the
NAc. (A) Illustration demonstrating in-vivo measurements of
DA via microdialysis. DA is measured in the samples via
electrochemical detection via HPLC. (B) Following increasing
doses of IP catharanthine injections, DA samples are taken and
measured at each concentration. Catharanthine increases
extracellular DA content in the nucleus accumbens (NAc).
Asterisks *, ** and *** indicate p < 0.05, p < 0.01 and p <
0.001 respectively.

[108.6, 401.5], p = 0.00604, 0.000283, 0.000292, 0.000185 respectively, Fig. 7B).
Effects of catharanthine on self-administration of ethanol in a 2-bottle choice paradigm
To determine whether catharanthine possesses anti-addictive properties, we tested EtOH
dependent mice divided into 2 groups, vehicle and catharanthine on EtOH drinking in a 24-hour
two-bottle choice paradigm. Due to catharanthine’s biphasic effects in elevating extracellular DA
levels and inhibiting evoked DA release in the NAc, we hypothesized that catharanthine would
both reduce drug craving and blunt the rewarding effects of EtOH, which would result in reduced
drinking in EtOH-dependent mice.
Following a 1-week period of habituation in the cages, we measured the mice’s baseline
EtOH drinking behavior over the course of one week by placing one bottle with 16% EtOH and
another bottle with water in the cages. We measured the bottle weights several times a day to
quantify the amount of EtOH consumed. We injected half of the mice with catharanthine base (10
mg/kg) and the other half with saline. Next, we exposed the mice to chronic EtOH vapors in an
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EtOH vapor chamber system with
16 hours of EtOH vapor per day.
Following a period of 5-weeks of
exposure

to

intermittent

EtOH

vapor, we tested EtOH drinking
again using the same procedure used
initially. Catharanthine base was
again IP injected into half of the
Figure 8. Effect of catharanthine on voluntary EtOH drinking. (A) Prior
to being exposed to ethanol (EtOH) vapor chambers, mice were tested
in the 24-hour two bottle choice (TBC) drinking paradigm for one week.
Catharanthine (10mg/kg) or saline IP injections were given once daily.
(B) After 5 weeks of exposure in EtOH vapor chambers we repeated
the TBC procedure. Results were inconclusive. Asterisks *, ** and
*** indicate p < 0.05, p < 0.01 and p < 0.001 respectively.

mice once per day. Surprisingly, we
found that catharanthine increased
both water and EtOH drinking prior

to EtOH chambers (F1,76 = 13.03, p = 0.000548; F1,76 = 12.23, p = 0.000788, Fig. 8A). There were
no statistical differences between groups after vapor chambers (Fig. 8B).
Catharanthine alleviates ethanol induced anxiety during withdrawal
Elevated plus maze. It is well known that withdrawal following heavy ethanol use can be
one of the most stressful experiences that humans or animals can undergo. It has also been well
established that ethanol use modulates the mesolimbic DA system, thus it has been theorized that
the intense craving experienced during withdrawal results from reduced DA release in the NAc.
Since catharanthine elevates extracellular DA levels, we theorized that catharanthine would reduce
drug craving during EtOH withdrawal, thereby also reducing anxiety. In an elevated plus maze
(EPM) paradigm, increased time spent in the open arm of the maze is correlated with reduced
anxiety. Mice will typically spend more time in the closed arms of the maze where they feel more
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protected, especially when they are stressed. We found that increased EtOH exposure significantly
decreased time spent in the open arm in both saline and catharanthine exposed mice (saline: F4, 10
= 8.67, p = 0.00274; catharanthine: F4, 10 = 9.17, p = 0.00221, Fig. 9A). Interestingly, mice exposed
to catharanthine significantly spent more time in the open arm of the maze compared to saline

Figure 9. Catharanthine alleviates alcohol withdrawal induced anxiety. (A, B) Mice were tested on the elevated plus
maze and marble burying procedures before exposure to alcohol and catharanthine (Control), after exposure to 1
week of EtOH drinking with once daily catharanthine sulfate (10 mg/kg) IP injections (Week 0) and once per week
during a chronic intermittent exposure (CIE) model to alcohol in alcohol vapor chambers. No catharanthine injections
were given during time spent in EtOH vapor chambers. Asterisks *, ** and *** indicate p < 0.05, p < 0.01 and p <
0.001 respectively. # indicates p < 0.05 for that groups respective control.

mice at all time points following exposure to EtOH (week 0: F1,4 = 30.1, p = 0.00537; week 1: F1,4
= 25.5, p = 0.0072; week 2: F1,4 = 15.0, p = 0.0179; week 3: F1,4 = 7.72, p = 0.0498; Fig. 9A). In a
Tukey HSD adjustment, we found that mice exposed to catharanthine at weeks 2 and 3 in the EtOH
vapor chambers spent significantly less time in the open arm compared to before the vapor
chambers, but not at week 1 in the vapor chamber (week 1: 95% CIs [-52.8, 39.4], p = 0.988; week
2: 95% CIs [-109.4, -17.2], p = 0.00763; week 3: 95% CIs [-100.4, -8.22], p = 0.0201, Fig. 9A).
Additionally, we found that mice exposed to saline significantly decreased the amount of time they
spent in the open arm compared to control at time points week 0, week 2 and at week 3, but not at
week 1 (week 0: 95% CIs [-109.1, -2.19], p = 0.0405; week 1: 95% CIs [-103.2, 3.81], p = 0.0719;
week 2: 95% CIs [-132.8, -25.8], p = 0.00449; week 3: [-143.1, -36.2], p = 0.0018, Fig. 9A).
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Marble burying. Marble burying is a behavioral paradigm that corresponds with natural
behaviors exhibited by mice in the wild. Mice naturally bury their food or other objects when
stressed, thus we can take advantage of this instinctive behavior to measure anxiety in the
laboratory. Increases in the number of marbles buried is correlated with increases in anxiety.
Oddly, we saw no significant differences between groups in the marble burying behavioral test
(Fig. 9B), however saline mice tended to decrease the number of marbles buried with more time
in the EtOH vapor chambers while catharanthine mice slightly increased the number of marbles
they buried. The comparison at week 3 between saline and catharanthine groups is suggestive of a
difference, but is not significant (F1,4 = 4.74, p = 0.0951, Fig. 9B). The lack of significant results
in marble burying could be due to the low sample size in our data.
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DISCUSSION
Catharanthine modulates dopamine release and reuptake in the nucleus accumbens
It has been well established that DA release in the nucleus accumbens (NAc) is involved
in learning and potentially mediating the rewarding properties of drugs of abuse. We have shown
in this study that catharanthine modulates DA release and reuptake in the NAc in the µM range,
indicating that catharanthine may potentially influence the hedonic properties of drugs of abuse
(Figs. 3-5). Our data suggests that catharanthine modulates DA through a biphasic mechanism
inhibiting vesicular DA release while also slowing DA reuptake through inhibition of the DAT.
Interestingly, we found that catharanthine sulfate inhibits DA release significantly more than
catharanthine base, which may be due to catharanthine sulfate’s increase aqueous solubility (Fig.
3). Next, we tested 18-methoxycoronaridine (18-MC) on DA release, a compound that is also a
coronaridine congener and has been found to decrease self-administration of EtOH and nicotine in
animals. We found that 18-MC weakly inhibits DA release in a concentration dependent manner,
but significantly less than catharanthine in a linear regression (Fig. 3).
Next, we wanted to determine the mechanism of action for catharanthine’s inhibition of
DA release in the NAc. We found that catharanthine’s inhibitory effects were significantly reduced
by DHβE, an α4 nAChR antagonist, with α-conotoxin MII, a selective α6 nAChR antagonist and
with mecamylamine, a general nAChR antagonist (Fig. 4). For this reason, we suggest that the
mechanism for catharanthine’s inhibition of DA release is via inhibition of nicotinic acetylcholine
receptors (nAChRs) containing either α4 or α6 subunits. Others have shown that catharanthine also
inhibits α3 nAChRs, which are also expressed on DA terminals and such are also likely to be
involved in catharanthine induced inhibition of DA release. We should also consider that the drugs
DHβE and MII may have weak affinity for other nAChR subunits, thus future experiments
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investigating this effect are warranted. It is currently unknown whether catharanthine induced
inhibition of DA release occurs via nAChRs expressed on DA pre-synaptic terminals or on
nAChRs expressed on CINs, however it is likely a combination of both.
Catharanthine’s second mechanism in modulating DA is through slowing DA reuptake
through inhibition of DATs expressed on DA pre-synaptic terminals (Fig. 3), which we were able
to confirm through iontophoresis experiments recording the reuptake of externally applied DA
onto a brain slice (Fig. 5). Due to catharanthine’s affinity for serotonin transporters (SERT) and
for dopamine’s slight affinity for SERTs, it is possible that part of this effect is mediated by
inhibition of SERTs. It appears that catharanthine base may have a greater affinity for the DAT,
due to catharanthine sulfate’s lack of a significant effect on downward velocity (Fig. 3). Future
experiments could include analysis of 18-MC and catharanthine base on DA reuptake via
iontophoresis, effect of α3 nAChR antagonists on catharanthine induced inhibition of DA release,
genetic knockouts of α4 and α6 nAChRs to confirm catharanthine’s mechanism of action and
analysis of the effect of catharanthine on isolated serotonin release via FSCV.
Effect of catharanthine on cholinergic interneuron and nicotinic acetylcholine receptor
excitability
Following our analysis of catharanthine on DA dynamics, we decided to determine whether
catharanthine has any effect on the firing rate of CINs in the NAc. CINs are important modulators
of DA release through releasing acetylcholine onto pre-synaptic terminals expressing nAChRs.
Using cell-attached mode patch clamp electrophysiology, we found that catharanthine inhibits CIN
firing rate in a concentration dependent manner with an IC50 of 30 µM (Fig. 6). This supports our
theory that catharanthine inhibits evoked DA release partially through inhibition of striatal CINs.
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Another future experiment we would like to do is test catharanthine on CIN firing rate in the
presence of EtOH. We have shown that EtOH increases CIN firing rate in slice through interaction
with nAChRs, thus it would be interesting to see if EtOH blocks catharanthine induced inhibition
of CIN firing rate. Lastly, we would also like to investigate the effect of 18-MC on CIN firing rate
and compare it with catharanthine to help us understand the differences seen in inhibition of DA
release.
Effects of catharanthine on dopamine dynamics in-vivo
To better understand the effects of catharanthine on DA dynamics in the brain, we decided
to measure extracellular levels of DA in a live animal using microdialysis and high performance
liquid chromatography (HPLC) combined with electrochemical detection. In-vivo measurements
are important to make because it shows you what happens to the brain on a systemic level. It is
likely that catharanthine modulates a large variety of different brain regions due to how widely
nAChRs are expressed in the brain. We hypothesized that catharanthine would slightly elevate
extracellular DA levels in the NAc due to its affinity for the DAT. We found that catharanthine
elevated DA levels to nearly 200% of the baseline at 5 mg/kg and to 250% of the baseline at 10
mg/kg (Fig. 7). Increasing doses of catharanthine to 20 and 50 mg/kg did not result in any further
increase in DA levels, which was unexpected due to our results in-vitro showing increasing
concentrations of catharanthine resulted in increased slowing of the DAT. It is possible that
catharanthine acts through an additional mechanism to elevate DA levels in the NAc, however we
currently don’t have any data to support that. Furthermore, we suspected that the increases in
extracellular DA observed following IP administration of catharanthine were due to catharanthine
oxidizing at a similar voltage as DA during the HPLC analysis, which would confound our results.
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So we tested catharanthine on its own and found that it did not oxidize similarly to dopamine in
our HPLC analysis.
Based on our data ex-vivo and in-vivo, we suggest that catharanthine elevates extracellular
DA levels in the NAc in mice through inhibition of the DAT, although it is possible that there are
nAChR effects influencing this phenomenon. Further experimentation is warranted to better
understand this effect. We suggest that further experiments investigate the effect of DAT knockouts on extracellular DA levels following administration of catharanthine. We hypothesize that
knock outs of the DAT would block the elevations in DA we observe in the NAc. Additional
experimentation could also investigate DA levels in different brain regions that don’t express the
DAT, such as the cerebellum.
Effect of catharanthine on mice behavior
Ethanol self-administration. To determine the suitability of catharanthine as a treatment
for addiction, we tested it on both EtOH self-administration and EtOH withdrawal induced anxiety
(Figs. 8, 9). Unfortunately, our self-administration data was inconclusive due to a poor
experimental design (Fig. 8). We were expecting to see a large increase in EtOH drinking
following a 5-week period in EtOH vapor chambers designed to induce dependence. Instead, the
mice drank nearly the same amount of EtOH following the vapor chambers compared to before
the vapor chambers. A potential reason for this lack of results could be that we did not use the
chronic intermittent exposure (CIE) model which has been shown to increase EtOH dependence.
The CIE model consists of 4 days with vapor on and 3 days with vapor off for the mice to
repeatedly go through withdrawal and to better learn the rewarding effects of EtOH. Our
experimental design consisted of exposing the mice to EtOH vapor for 16 hours from 10 AM to 2
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AM every day. Additionally, we started doing injecting pyrazole, an alcohol dehydrogenation
inhibitor, once every 3 days half way through the 5-week period in the vapor chambers to slow
EtOH metabolism in the mice. Pyrazole injections have been shown to increase blood EtOH levels
in mice and to increase dependence, so it is possible that we didn’t do pyrazole injections for
enough time. Lastly, we also did not wait for sufficient time following the end of the EtOH vapor
chambers to induce withdrawal before collecting EtOH drinking data. Mice will binge drink to
dependence after several days of feeling the negative effects of withdrawal. We propose to redo
this drinking experiment with the above mentioned adjustments to better understand the effect of
catharanthine on drug craving and drug use.
Ethanol withdrawal induced anxiety. Withdrawal from heavy EtOH use has a large variety
of negative side effects in both humans and animals, among them being severe anxiety. A
pharmaceutical treatment that reduces anxiety during EtOH withdrawal, thereby reducing the
negative reinforcing effects of EtOH, could potentially reduce drug craving. We found that
catharanthine reduces anxiety-like behaviors during EtOH withdrawal, specifically in the amount
of time that they spend in the open arm of the elevated plus maze (Fig. 9). In these experiments,
we tested mice before and during exposure to EtOH vapor chambers in a CIE model of 4 days of
vapor with 3 days without vapor. We tested mice in both the elevated plus maze and marble
burying paradigms once a week on the first day without vapor, 10 hours into withdrawal.
Significant differences were noted between catharanthine and vehicle groups on each time point
tested, indicating that catharanthine has an anxiolytic effect in mice. We also observed a significant
decrease in the time the control group spent on the open arm, indicating that the withdrawal from
the EtOH vapor chambers was anxiety inducing. It is known that there are residual effects from
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testing mice in the EPM repeatedly, which may partly confound our results. However, due to the
significant differences seen between the catharanthine and vehicle mice, this is not likely to overly
influence the data.
There remains a lot of work to do in fully determining the effects catharanthine has on the
brain and whether catharanthine is a suitable treatment for addiction. Due to catharanthine being a
naturally occurring substance, it could potentially be acting on other receptors, further influencing
behavior in unexpected ways. Future studies investigating catharanthine should determine its
effects in different brain regions, different neurotransmitters in the brain and further characterize
its effect on drug seeking behavior in rodents.
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